New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.
Effect on Travel Distance of a Statewide Regionalization Policy for Initial Breast Cancer Surgery The use of 90 mg/m 2 daunorubicin once daily in the context of classical 7 + 3 induction does not ...
In PV and ET, MDS risk remains lower than AML risk but increases progressively with advancing attained age. Transformation to acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results